Zobrazeno 1 - 10
of 298
pro vyhledávání: '"C D, Buckner"'
Autor:
Kevin A. Schulman, Lesley H. Curtis, C D Buckner, Kevin P. Weinfurt, K Bajwa, Barbara Wilson-Relyea, C H Weaver
Publikováno v:
Bone Marrow Transplantation. 29:159-164
Filgrastim alone and sequential sargramostim and filgrastim have been shown to be more effective than sargramostim alone in the mobilization of CD34(+) cells after myelosuppressive chemotherapy (MC). We sought to compare costs and resource use associ
Autor:
David G. Maloney, Oliver W. Press, Heather Hooper, C. D. Buckner, F R Appelbaum, F Gutierrez-Delgado, William I. Bensinger, R. T. Maziarz, JB Golden, Leona Holmberg
Publikováno v:
Bone Marrow Transplantation. 28:455-461
The aim of this study was to compare toxicity and efficacy of total body irradiation (TBI), cyclophosphamide (CY) and etoposide (E) (TBI/CY/E) vs busulfan, melphalan and thiotepa (Bu/Mel/T) in patients receiving autologous stem cell infusion (ASCI) f
Publikováno v:
Journal of Hematotherapy. 8:103-113
Several studies have clearly documented a more rapid hematopoietic recovery with growth factor-mobilized PBSC than with bone marrow. Time to engraftment for neutrophils and platelets average 8-12 days in contrast to 2-4 weeks after bone marrow. This
Publikováno v:
Hematology. 3:107-117
The desire to remove tumor cells from autologous grafts is strong and commitments to this approach for ASCT have reached religious proportions. There is a general "feeling" by many investigators, the public and some private companies that grafts shou
Publikováno v:
Journal of animal science. 91(7)
Effects of organic and inorganic sources of S on intake, intake pattern, ruminal pH, VFA profile, and ruminal H2S gas concentration ([H2S]) were evaluated, which lead to development of a procedure to measure ruminal S availability for reduction [rumi
Autor:
C D, Buckner, T J, Klopfenstein, K M, Rolfe, W A, Griffin, M J, Lamothe, A K, Watson, J C, MacDonald, W H, Schacht, P, Schroeder
Publikováno v:
Journal of animal science. 91(6)
Four experiments were conducted to evaluate RUP content and digestibility for smooth bromegrass, subirrigated meadow, upland native range, and warm-season grasses. Samples were collected from esophageally cannulated cows or ruminally cannulated steer
Autor:
J E, Anderson, F R, Appelbaum, G, Schoch, T, Gooley, C, Anasetti, W I, Bensinger, E, Bryant, C D, Buckner, T R, Chauncey, R A, Clift, K, Doney, M, Flowers, J A, Hansen, P J, Martin, D C, Matthews, J E, Sanders, H, Shulman, K M, Sullivan, R P, Witherspoon, R, Storb
Publikováno v:
Blood. 87:51-58
From 1990 to 1993 we performed a prospective study of busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) in 30 patients with refractory anemia (RA) undergoing related (n = 17) or unrelated (n = 13) donor marrow transplantation. Nineteen patients su
Autor:
W. I. Bensinger, K. Longin, F. Appelbaum, S. Rowley, C. Weaver, K. Lilleby, T. Gooley, M. Lynch, T. Higano, J. Klarnet, T. Chauncey, R. Storb, C. D. Buckner
Publikováno v:
British Journal of Haematology. 87:825-831
Factors affecting mobilization and engraftment were analysed in 54 patients undergoing transplant using autologous PBSCs mobilized with high-dose recombinant granulocyte stimulating factor (rhG-CSF). Patients received 5-7 d of rhG-CSF, 16 micrograms/
Autor:
Jean E. Sanders, C. D. Buckner, Oliver W. Press, Gary Schoch, Stephen W. Crawford, L D Fisher, J E Anderson, Finn Bo Petersen, F R Appelbaum, M R Litzow
Publikováno v:
Journal of Clinical Oncology. 11:2342-2350
PURPOSE To analyze results of 127 patients undergoing myeloablative therapy followed by marrow transplantation for relapsed or refractory Hodgkin's disease. PATIENTS AND METHODS Twenty-three patients had primary refractory disease, 34 were in early f
Autor:
M C Benyunes, Alexander Fefer, John A. Thompson, A York, C. Massumoto, Catherine G. Lindgren, C. Higuchi, C. D. Buckner
Publikováno v:
Acta Haematologica. 89:2-7
Patients who undergo autologous bone marrow transplantation (ABMT) for advanced hematologic malignancies experience a high relapse rate. Therapy with interleukin-2 (IL-2) +/- lymphokine-activated killer (LAK) cells has induced clinical responses in s